Copyright
©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Clin Oncol. Jul 10, 2011; 2(7): 299-302
Published online Jul 10, 2011. doi: 10.5306/wjco.v2.i7.299
Published online Jul 10, 2011. doi: 10.5306/wjco.v2.i7.299
An oral fluoropyrimidine agent S-1 induced interstitial lung disease: A case report
Hiromichi Yamane, Masahide Kinugawa, Shigeki Umemura, Yasuhiro Shiote, Kenichiro Kudo, Toshimitsu Suwaki, Haruhito Kamei, Division of Clinical Oncology, Sumitomo-Besshi Hospital Cancer Center, 3-1 Ohji-cho, Niihama, Ehime 792-8543, Japan
Hiromichi Yamane, Nagio Takigawa, 4th Department of General Medicine, Kawasaki Medical School, 2-1-80 Nakasange, Okayama 700-8505, Japan
Nagio Takigawa, Katsuyuki Kiura, Department of Respiratory Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama, Okayama 700-8558, Japan
Author contributions: Yamane H and Kinugawa M analyzed the bibliographical data; Yamane H, Kinugawa M, Umemura S, Shiote Y, Kudo K, Suwaki T and Kamei H were involved in the case of the patient; Yamane H, Takigawa N and Kiura K wrote the paper.
Correspondence to: Hiromichi Yamane, MD, PhD, Director, Division of Clinical Oncology, Sumitomo-Besshi Hospital Cancer Center, 3-1Ohji-cho, Niihama, Ehime 792-8543, Japan. hiromichi_yamane@ni.sbh.gr.jp
Telephone: +81-897-377111 Fax: +81-897-377121
Received: March 22, 2011
Revised: May 19, 2011
Accepted: May 26, 2011
Published online: July 10, 2011
Revised: May 19, 2011
Accepted: May 26, 2011
Published online: July 10, 2011
Core Tip